KKR Biosimilar L.P.
An insider at 1 company in coverage, as reported on Form 4. SEC CIK 1624314. Latest Form 4 filed Nov 14, 2014.
Roles
As stated on the filings: the relationship to the company and any officer title.
| Company | Role | Transactions | First | Latest |
|---|---|---|---|---|
| Coherus Oncology, Inc.CHRS | 10% owner | 2 | 2014-11-12 | 2014-11-12 |
Transactions: 2
Every transaction reported, newest first, including grants, exercises and derivative securities. Purchases and sales (codes P and S) are open-market trades. The reported price is as stated on the form.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
| Date | Company | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2014-11-12 | Coherus Oncology, Inc.10% owner | ConversionSeries C Preferred Stock | 2,499,499 | $0.00 | $0 | Form 4 |
| 2014-11-12 | Coherus Oncology, Inc.10% owner | Conversion | 2,499,499 | not reported | not reported | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Nov 1, 2026, 11:35 ET. Listed shows no prices and gives no investment advice.